Lutetium Lu-177

Drugmakers like Bristol Myers Squibb, AstraZeneca, and Eli Lilly invest billions in radiopharmaceuticals, which deliver radiation directly to tumors. These drugs, in development for various cancers, attach radioactive material to targeting molecules, sparing healthy cells. Novartis' successes with Lutathera and Pluvicto have spurred interest, but manufacturing and logistics remain complex. The market potential ranges from $5 billion to tens of billions, depending on efficacy across cancer types.

Peter Macallum Cancer Centre's UpFrontPSMA study shows LuPSMA therapy significantly improves outcomes for newly diagnosed prostate cancer patients, with 41% achieving undetectable PSA at 48 weeks compared to 16% with standard-of-care. The results were published in *Lancet Oncology* and presented at ESMO 2024.

Roche's subcutaneous Tecentriq approved for cancer treatment; Gilead's twice-yearly HIV shot reduces infection risk by 96%; Biogen appoints Lloyd Minor and Menelas Pangalos as independent directors; Sanofi secures rights to a rare cancer radiopharmaceutical; Eli Lilly to expand Irish manufacturing for Alzheimer's drug Kisunla.

The Lutetium-177 market, valued at USD 167.7 million in 2023, is projected to grow at a CAGR of 21.44% to USD 653.53 million by 2030, driven by its use in cancer treatment and the rise in cancer incidence. Non-carrier-added Lu-177, due to its higher purity, is gaining traction for targeted therapies, reducing side effects and radioactive waste. Key applications include treating neuroendocrine tumors and prostate cancer, with ongoing research exploring its potential in other medical areas. Market growth is supported by technological advancements in radiopharmaceuticals, increased government healthcare funding, and an aging population, though challenges include stringent regulations and high production costs.

Theranostics, precision medicine using PET imaging to identify targets for therapy, has evolved rapidly in nuclear medicine. Examples include 18F-FGFR1 for FGFR1-expressing tumors, 89Zr-girentuximab for hypoxia imaging, and PSMA-targeted radiotracers for ccRCC. Clinical applications like PSMA-targeted theranostics in non-prostate cancers and individualized dosimetry with lutetium-177-labeled agents are discussed. The potential of digital twins for personalized dosing is also highlighted, emphasizing the need for continued research and technological advancements.

Novartis to present ASC4FIRST Phase III study results for Scemblix® in first-line Ph+ CML-CP at ASCO and EHA, highlighting its potential as a Breakthrough Therapy. Also, NATALEE trial data for Kisqali® in HR+/HER2- early breast cancer and updates on radioligand therapy portfolio will be shared.

SHINE Medical Technologies partners with Nucleus RadioPharma to supply lutetium-177 for targeted radiopharmaceutical treatments, enhancing cancer care. This agreement ensures a steady supply for innovative therapies, supporting clinical trials and patient access to advanced treatments.

Targeted alpha therapy delivers cytotoxic alpha radiation to tumor cells, sparing healthy tissue. It uses radiopharmaceuticals with radionuclides, targeting vectors, and delivery formulations. Challenges include daughter isotope retention and complex dosimetry. Advances in nanoformulations and theranostic pairs aim to overcome these, promising improved cancer treatment outcomes.